retatrutide trial sign up australia Lilly's 'triple G' agonist triumphs in Phase III trial, but AEs unnerve analysts Retatrutide Phase 3: TRIUMPH Program

FDA (Food and Drug Administration) approval it may revolutionise the way we approach the management of obesity and being overweight

Clinical trials suggest retatrutide dosing will start low, with incremental increase every four weeks, similarly to drugs like Zepbound and Wegovy

The safest approach

Lets explore the transformative power of injections and initiate a journey towards a healthier, happier you

The findings were consistent: patients experienced measurable increases in hair density (9.5 to 35 additional hairs per square centimeter) and hair thickness (up to 13 micrometers)

At 12mg, participants lost an average of 28.7% of their body weight, which translates to approximately 71 pounds from a baseline average of 248 pounds